M&A / Deals Daiichi exits OTC, with $1.55bn unit sale to Suntory PharmaphorumDaiichi Sankyo has agreed to sell its consumer health unit to food and beverage giant Suntory, following a well-trodden path for big pharma companies.M&A / DealsRead full story pharminent April 15, 2026 Pharmaphorum Daiichi Sankyo has agreed to sell its consumer health unit to food and beverage giant Suntory, following a well-trodden path for big pharma companies. M&A / DealsRead full story Post navigation Previous: BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debutNext: Parkinson’s charity partners Biognosys on biomarker project Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
